Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AXSM Stock Price Chart Interactive Chart >
AXSM Price/Volume Stats
| Current price | $29.72 | 52-week high | $87.24 |
| Prev. close | $28.53 | 52-week low | $19.38 |
| Day low | $27.80 | Volume | 1,354,900 |
| Day high | $29.79 | Avg. volume | 659,456 |
| 50-day MA | $37.47 | Dividend yield | N/A |
| 200-day MA | $59.86 | Market Cap | 1.12B |
Axsome Therapeutics, Inc. (AXSM) Company Bio
Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.
Latest AXSM News From Around the Web
Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12. |
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in NarcolepsyNEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a Mechanistic Approach to Treating Narcolepsy), a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-12 in patients with narcolepsy. AXS-12 is a novel, oral, potent, and highly selective norepinephrine reuptake inhibitor. T |
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA AcceptanceAxsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine. |
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of MigraineNEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine, and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2022 for the NDA. AXS-07 (MoSEIC™ |
Axsome Therapeutics Inc Ranked Among Todays Top Shorts After The European Central Bank Says It May Slow Down Bond PurchasesThe post Axsome Therapeutics Inc Ranked Among Todays Top Shorts After The European Central Bank Says It May Slow Down Bond Purchases appeared on BitcoinEthereumNews.com . Getty For the second week in a row, we hit a pandemic-era low in jobless claims. This is a very welcome positive signal for the market and the labor situation. |
AXSM Price Returns
| 1-mo | 37.85% |
| 3-mo | -58.23% |
| 6-mo | -49.14% |
| 1-year | -63.60% |
| 3-year | 814.46% |
| 5-year | 284.48% |
| YTD | -63.52% |
| 2020 | -21.18% |
| 2019 | 3,565.25% |
| 2018 | -49.64% |
| 2017 | -17.04% |
| 2016 | -27.18% |
Loading social stream, please wait...